Hamooya Benson M, Siame Lukundo, Mutalange Matenge, Cheelo Chilala, Kamvuma Kingsley, Masenga Sepiso K, Chitalu Chanda, Shrestha Sadeep, Bosomprah Samuel
Mulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Department of Internal Medicine, Livingstone University Teaching Hospital, Livingstone, Zambia.
PLoS One. 2025 Sep 8;20(9):e0330777. doi: 10.1371/journal.pone.0330777. eCollection 2025.
Overweight and obesity are major concerns among people living with HIV (PLWH), particularly those on integrase inhibitors, as they elevate the risk of cardiovascular diseases. However, longitudinal data on the burden and risk factors for overweight/obesity in sub-Saharan Africa (SSA) remain limited. This study aimed to estimate the incidence and identify factors associated with overweight and obesity among PLWH who switched to a dolutegravir (DTG)-based ART regimen at Livingstone University Teaching Hospital.
We enrolled 249 adults aged ≥18 years living with HIV on ART [non-nucleoside/nucleotide reverse transcriptase inhibitor (NNRTI) n = 174, protease inhibitor (PI) n = 21, and DTG n = 54] with a baseline body mass index (BMI) < 25 kg/m² between April 2019 and May 2020 and conducted a single follow-up assessment between December 2022 and June 2023. Participants were followed for a median of 43 months (interquartile range [IQR]: 42, 44). At follow-up, all participants were on a DTG-based regimen for a median time of 23 months (IQR: 19, 40). Demographic, clinical, and laboratory data were collected using a structured questionnaire. The primary outcome was overweight/obesity, defined as BMI ≥ 25 kg/ m2. Poisson regression with robust standard errors was used to determine risk factors for being overweight and obesity.
The median age was 44 years (interquartile range (IQR) 36, 51) at baseline, with the majority being female (59.4%, n = 148). Over a total follow-up of 871.5 person-years, 44 incident cases of overweight/obesity occurred, yielding a cumulative incidence of 17.7% (44/249) and an incidence rate of 5.05 per 100 person-years. Factors positively associated with the risk of being overweight/obesity included being married (adjusted incidence rate ratio [aIRR] 2.34; 95% CI 1.24, 4.40), lower baseline CD4 count (aIRR 4.13; 95% CI 1.41, 13.38) and higher waist circumference (WC) values (aIRR 1.07; 95% CI 1.03, 1.11). While older age was associated with a lower risk of overweight/obesity (aIRR 0.97; 95% CI 0.94, 0.99).
The burden of overweight/obesity was high, and it was significantly driven by demographic, anthropometric, and immunological factors among our study participants. The findings suggest the importance of implementing targeted screening and management strategies for overweight and obesity, particularly among married individuals with higher WC values. Studies investigating the underlying mechanisms of excessive weight gain among PLWH on an integrase inhibitor-based regimen in resource-limited settings are warranted.
超重和肥胖是艾滋病毒感染者(PLWH)主要关注的问题,尤其是那些使用整合酶抑制剂的患者,因为这会增加心血管疾病的风险。然而,撒哈拉以南非洲(SSA)超重/肥胖负担及危险因素的纵向数据仍然有限。本研究旨在估计在利文斯通大学教学医院改用基于多替拉韦(DTG)的抗逆转录病毒治疗方案的PLWH中超重和肥胖的发病率,并确定相关因素。
我们纳入了249名年龄≥18岁且正在接受抗逆转录病毒治疗的艾滋病毒感染者[非核苷/核苷酸逆转录酶抑制剂(NNRTI)组n = 174,蛋白酶抑制剂(PI)组n = 21,DTG组n = 54],他们在2019年4月至2020年5月期间的基线体重指数(BMI)<25kg/m²,并在2022年12月至2023年6月期间进行了一次随访评估。参与者的随访时间中位数为43个月(四分位间距[IQR]:42,44)。在随访时,所有参与者均接受基于DTG的治疗方案,治疗时间中位数为23个月(IQR:19,40)。使用结构化问卷收集人口统计学、临床和实验室数据。主要结局为超重/肥胖,定义为BMI≥25kg/m²。采用稳健标准误的泊松回归来确定超重和肥胖的危险因素。
基线时的年龄中位数为44岁(四分位间距[IQR] 36,51),大多数为女性(59.4%,n = 148)。在总共871.5人年的随访中,发生了44例超重/肥胖事件,累积发病率为17.7%(44/249),发病率为每100人年5.05例。与超重/肥胖风险呈正相关的因素包括已婚(调整后的发病率比[aIRR] 2.34;95%置信区间1.24,4.40)、较低的基线CD4细胞计数(aIRR 4.13;95%置信区间1.41,13.38)和较高的腰围(WC)值(aIRR 1.07;95%置信区间1.03,1.11)。而年龄较大与超重/肥胖风险较低相关(aIRR 0.97;95%置信区间0.94,0.99)。
超重/肥胖负担较高,在我们的研究参与者中,其受到人口统计学、人体测量学和免疫学因素的显著影响。研究结果表明,实施针对超重和肥胖的靶向筛查和管理策略非常重要,特别是在WC值较高的已婚个体中。有必要开展研究,调查在资源有限环境中接受基于整合酶抑制剂方案治疗的PLWH体重过度增加的潜在机制。